secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001493152-26-006343
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 8.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma raises up to $21M via convertible preferred stock; board adds Balatsos
--------------------------------------------------------------------------------

- Initial closing of 13,750 Series A Convertible Preferred Shares for $11M gross proceeds; up to $21M total available.
- Preferred shares convertible into common at 80% of lowest 5-day VWAP prior to conversion, subject to 4.99% ownership cap.
- Company expects to regain Nasdaq stockholders' equity compliance (min $2.5M) after the offering.
- Donald G. Fell resigned from board; Philip Balatsos appointed to fill vacancy.
- RBW Capital Partners acted as placement agent; proceeds to support operations and reduce legacy debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/0001493152-26-006343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer